Revenue Insights: Vertex Pharmaceuticals Incorporated and Evotec SE Performance Compared

Biotech Giants: Vertex vs. Evotec Revenue Growth

__timestampEvotec SEVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201489496000580415000
Thursday, January 1, 20151276770001032336000
Friday, January 1, 20161645070001702177000
Sunday, January 1, 20172576300002488652000
Monday, January 1, 20183754050003047597000
Tuesday, January 1, 20194464370004162821000
Wednesday, January 1, 20205009240006205683000
Friday, January 1, 20216180340007574400000
Saturday, January 1, 20227514480008930700000
Sunday, January 1, 20237814260009869200000
Monday, January 1, 202411020100000
Loading chart...

Data in motion

Revenue Growth: Vertex Pharmaceuticals vs. Evotec SE

In the competitive landscape of biotechnology, Vertex Pharmaceuticals Incorporated and Evotec SE have shown remarkable revenue trajectories over the past decade. From 2014 to 2023, Vertex Pharmaceuticals has experienced a staggering growth, with its revenue increasing by over 1,600%, reaching nearly $9.9 billion in 2023. This growth underscores Vertex's strategic advancements in the pharmaceutical sector, particularly in the development of innovative therapies.

Conversely, Evotec SE, while not matching Vertex's explosive growth, has demonstrated a steady increase in revenue, growing by approximately 770% over the same period. By 2023, Evotec's revenue approached $781 million, reflecting its consistent expansion in the drug discovery and development market.

This comparison highlights the dynamic nature of the biotech industry, where strategic innovation and market positioning can lead to significant financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025